June 13, 2025 Obicetrapib May Offer LDL Benefit In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy. Conexiant
Pharmacologic Toll-like Receptor 4 Inhibition Ameliorates Early Astrogliosis Improving Neurocognitive Outcomes Following Traumatic Brain Injury